Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. More Details
Established dividend payer with limited growth.
Share Price & News
How has Ryman Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RHCG.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how RHCG.F performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how RHCG.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Ryman Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Ryman Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: RHCG.F ($7.6) is trading above our estimate of fair value ($3.31)
Significantly Below Fair Value: RHCG.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RHCG.F is poor value based on its PE Ratio (26.2x) compared to the US Healthcare industry average (22.2x).
PE vs Market: RHCG.F is poor value based on its PE Ratio (26.2x) compared to the US market (17.6x).
Price to Earnings Growth Ratio
PEG Ratio: RHCG.F is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: RHCG.F is overvalued based on its PB Ratio (3x) compared to the US Healthcare industry average (2.8x).
How is Ryman Healthcare forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RHCG.F's forecast earnings growth (13.2% per year) is above the savings rate (2.2%).
Earnings vs Market: RHCG.F's earnings (13.2% per year) are forecast to grow slower than the US market (22.9% per year).
High Growth Earnings: RHCG.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: RHCG.F's revenue (11.2% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: RHCG.F's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RHCG.F's Return on Equity is forecast to be low in 3 years time (14%).
How has Ryman Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RHCG.F has a large one-off gain of NZ$144.4M impacting its March 31 2020 financial results.
Growing Profit Margin: RHCG.F's current net profit margins (62.5%) are lower than last year (85.4%).
Past Earnings Growth Analysis
Earnings Trend: RHCG.F's earnings have grown by 3% per year over the past 5 years.
Accelerating Growth: RHCG.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RHCG.F had negative earnings growth (-18.8%) over the past year, making it difficult to compare to the Healthcare industry average (31.1%).
Return on Equity
High ROE: RHCG.F's Return on Equity (11.5%) is considered low.
How is Ryman Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: RHCG.F's short term assets (NZ$470.5M) do not cover its short term liabilities (NZ$697.0M).
Long Term Liabilities: RHCG.F's short term assets (NZ$470.5M) do not cover its long term liabilities (NZ$4.7B).
Debt to Equity History and Analysis
Debt Level: RHCG.F's debt to equity ratio (76.7%) is considered high.
Reducing Debt: RHCG.F's debt to equity ratio has increased from 37.5% to 76.7% over the past 5 years.
Debt Coverage: RHCG.F's debt is well covered by operating cash flow (25.5%).
Interest Coverage: RHCG.F's interest payments on its debt are not well covered by EBIT (2.4x coverage).
What is Ryman Healthcare current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: RHCG.F's dividend (1.75%) is higher than the bottom 25% of dividend payers in the US market (1.72%).
High Dividend: RHCG.F's dividend (1.75%) is low compared to the top 25% of dividend payers in the US market (4.94%).
Stability and Growth of Payments
Stable Dividend: RHCG.F's dividends per share have been stable in the past 10 years.
Growing Dividend: RHCG.F's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (45.7%), RHCG.F's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: RHCG.F's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Gordon MacLeod has been the Chief Executive Officer since July 1, 2017 of Ryman Healthcare Limited since October 26, 2006 and serves as its Secretary and served as its Deputy Chief Executive and Chief ...
CEO Compensation Analysis
Compensation vs Market: Gordon's total compensation ($USD888.03K) is below average for companies of similar size in the US market ($USD5.74M).
Compensation vs Earnings: Gordon's compensation has been consistent with company performance over the past year.
|CEO & Secretary||3.17yrs||NZ$1.36m||0.14% |
|Chief Financial Officer||3.25yrs||no data||0.031% |
|Chief Operations Officer||0.67yr||no data||0.0085% |
|Chief People & Technology Officer||1.67yrs||no data||0.022% |
|Acting Chief of Sales & Marketing Officer||0.67yr||no data||0.0048% |
|Chief Development Officer||0.67yr||no data||0.018% |
|Corporate Affairs Manager||no data||no data||no data|
|Investor Relations Manager||no data||no data||no data|
Experienced Management: RHCG.F's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
|Independent Chairman of the Board||21.67yrs||NZ$222.00k||0.072% |
|Advisor to the Board||3.33yrs||NZ$2.73m||no data|
|Independent Non-Executive Director||7.67yrs||NZ$136.25k||0.011% |
|Independent Deputy Chairman||no data||NZ$128.50k||0.00030% |
|Independent Non-Executive Director||11.67yrs||NZ$110.50k||0.016% |
|Independent Non-Executive Director||6yrs||NZ$136.25k||0.0031% |
|Independent Director||0.83yr||NZ$38.68k||no data|
|Independent Director||1.92yrs||NZ$128.50k||0.0020% |
Experienced Board: RHCG.F's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RHCG.F insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ryman Healthcare Limited's company bio, employee growth, exchange listings and data sources
- Name: Ryman Healthcare Limited
- Ticker: RHCG.F
- Exchange: OTCPK
- Founded: 1984
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: NZ$6.892b
- Listing Market Cap: NZ$4.512b
- Shares outstanding: 497.29m
- Website: https://www.rymanhealthcare.co.nz
Number of Employees
- Ryman Healthcare Limited
- Airport Business Park
- 92 Russley Road
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RYM||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Jun 1999|
|RHCG.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 1999|
|RH7||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 1999|
|RYHT.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Nov 2011|
Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. Its villages offer a range of retirement living ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/27 05:54|
|End of Day Share Price||2020/07/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.